Sanofi Under Fire by Senate Panel For Competition Delaying Tactics

Sanofi contributed more than $5 million to two medical groups and a researcher as part of a coordinated campaign to delay the approval of generic alternatives to Lovenox, the company's blockbuster blood-thinner, a U.S. Senate Finance Committee investigation has found.

Read more of this story from SeekingAlpha.com here.

About the Author

Pharmaceutical Manufacturing Staff

Pharmaceutical Manufacturing Staff

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates